Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Orquest

This article was originally published in The Gray Sheet

Executive Summary

Orquest: Firm plans to commence U.S. clinical trials of its Healos bone grafting material for spinal fusion in early 1998 under an investigational device exemption submission by strategic development partner Spine-Tech, Michael Estes, president and CEO, states at the recent BancAmerica Robertson Stephens conference in New York City. Orquest also has a research agreement with Hoechst Marion Roussel for evaluation of Healos with Hoechst growth factors. The privately held, Mountain View, California firm is also preparing for clinical trials of its Ossigel injectable product for accelerating the healing of fractures...



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts